Real-time
Other stock markets
|
5-day change | 1st Jan Change | ||
0.313 EUR | -6.43% | -10.06% | -19.74% |
Apr. 04 | Celyad Oncology SA Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Feb. 09 | Celyad Oncology Seeks Termination of Reporting Obligations to US SEC | MT |
Sales 2022 | - | Sales 2023 | 102K 109K | Capitalization | 16.16M 17.25M |
---|---|---|---|---|---|
Net income 2022 | -40M -42.71M | Net income 2023 | -8M -8.54M | EV / Sales 2022 | - |
Net cash position 2022 | 12.19M 13.02M | Net cash position 2023 | 5.95M 6.35M | EV / Sales 2023 | 100 x |
P/E ratio 2022 |
-0.28
x | P/E ratio 2023 |
-1.19
x | Employees | 18 |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 92.37% |
Latest transcript on Celyad Oncology SA
1 day | -6.43% | ||
1 week | -10.06% | ||
Current month | -10.83% | ||
1 month | -11.08% | ||
3 months | -11.58% | ||
6 months | -56.04% | ||
Current year | -19.74% |
Managers | Title | Age | Since |
---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
David Georges
DFI | Director of Finance/CFO | - | 18-12-31 |
Eytan Breman
CTO | Chief Tech/Sci/R&D Officer | - | 14-12-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Michel Lussier
FOU | Founder | 67 | 07-07-23 |
Hilde Windels
CHM | Chairman | 59 | 18-05-06 |
Serge Goblet
BRD | Director/Board Member | - | 07-12-31 |
Date | Price | Change | Volume |
---|---|---|---|
24-04-18 | 0.313 | -6.43% | 2 177 |
24-04-17 | 0.3345 | -1.47% | 16,912 |
24-04-16 | 0.3395 | -0.15% | 10,241 |
24-04-15 | 0.34 | +6.25% | 10,091 |
24-04-12 | 0.32 | -8.05% | 33,574 |
Real-time Euronext Bruxelles, April 18, 2024 at 06:57 am EDT
More quotesAnnual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.74% | 14.74M | |
-1.78% | 41.36B | |
+45.55% | 41.3B | |
+4.01% | 39.61B | |
-15.14% | 25.62B | |
+3.16% | 24.09B | |
-24.08% | 18.38B | |
-2.67% | 11.82B | |
+24.76% | 11.85B | |
+7.01% | 11.07B |
- Stock Market
- Equities
- CYAD Stock